Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05905731
Other study ID # LTCR-CHB-2-1
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date June 1, 2023
Est. completion date June 2026

Study information

Verified date June 2023
Source Beijing 302 Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single center, single arm, open label study to assess the safety, tolerability and effectiveness of the autologous HBV specific T cell receptor (HBV-TCR) redirected T cells in patients with chronic hepatitis B with ongoing with nucleos(t)ide analogue (NUC) treatment. This study will be conducted sequentially starting with Stage-1, followed by Stage-2.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 20
Est. completion date June 2026
Est. primary completion date June 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - HBsAg Positive, HBeAg Negative, Anti-HBe Positive (with HBeAg seroconversion). - On first-line treatment with oral nucleoside analogs antiviral drug therapy for more than a year. - Adequate organ function - Willing to stop and/or not to be on other immunomodulators during the study period, and to inform in time when other treatments such as glucocorticoids are needed - Liver biopsy, Fibroscan® or equivalent test obtained within the past 6 months demonstrating liver disease consistent with chronic HBV infection without evidence of bridging fibrosis or cirrhosis (= Metavir 3, recommended cut-off for Fibroscan 9.0kPa) - Females of childbearing potential must have a negative pregnancy test at Screening (within 3 days prior to first dose) and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been in menopause at least 2 years, or had tubal ligation at least 1 year prior to Screening, or who have had total hysterectomy. Willing and able to comply with all study procedures. - Willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures. Exclusion Criteria: - History of Acute infection, gastrointestinal bleeding, etc. occurring within 28 days prior to study enrollment. - Advanced liver cirrhosis, Child-Pugh score = 7 or clinical symptoms of liver function decompensation such as ascites and varicose veins - Positive test for other viral infections, anti-HAV IgM, anti HCV, anti-HDV, anti -HEV and anti-HIV Any item is positive; liver disease caused by other reasons (such as autoimmune liver disease, alcoholic liver disease, non-alcoholic liver disease, drug-induced liver disease and other liver diseases of unknown cause, etc.). - History of or suspicion of hepatocellular carcinoma or alpha fetoprotein (AFP) > 20 ng/mL at Screening. If AFP > 20 ng/mL, hepatic imaging must exclude hepatocellular carcinoma. - History of having received (in the last 6 months) or currently receiving any other cell therapies - History of organ transplantation - History of severe allergic reaction (hives or anaphylaxis) to blood products - History of any Grade 4 immune-related AE from prior immunotherapy. Any immune-related AE that led to permanent discontinuation that occurred less than 6 months prior to leukapheresis or whole blood collection for production - Use of any investigational product (IP) within 28 days of study treatment administration. - Lack of peripheral venous or central venous access or any condition that would interfere with drug administration or collection of study samples

Study Design


Intervention

Biological:
TCR-T
Stage-1: Patients will receive three biweekly HBV-TCR T cell infusions at escalating doses, ranging from 1 x 10^5 cells/kg to 5 x 10^6 cells/kg bodyweight (by IV infusion). Patients are to remain on existing HBV NUC treatment. Stage-2: Patients will receive three biweekly HBV-TCR T cell infusions at maximum dose as determined in Stage-1 study. Patients are to remain on existing HBV NUC treatment.

Locations

Country Name City State
China The Fifth Medical Center of PLA General Hospital Beijing

Sponsors (1)

Lead Sponsor Collaborator
Beijing 302 Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety evaluation of HBV-TCR T cell treatment Incidence of adverse events/serious adverse events Start of Treatment until 28 days post last dose
Secondary To evaluate the capability of HBV-TCR T cell treatment to lower the levels of serum HBsAg This is based on quantitative changes of HBsAg levels from baseline Start of treatment until 12 months post treatment follow-up
See also
  Status Clinical Trial Phase
Recruiting NCT04496882 - Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue Phase 4
Completed NCT04083716 - A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults Phase 1
Not yet recruiting NCT03038802 - A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection Phase 1/Phase 2
Completed NCT05310487 - Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects Phase 1
Recruiting NCT06070051 - Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy Phase 1
Terminated NCT05001022 - A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects Phase 1
Recruiting NCT04139850 - The Establishment of Korean Hepatitis B Patients Cohort
Recruiting NCT05343481 - Efficacy of VTP-300 in Chronic Hepatitis B Infection Phase 2
Not yet recruiting NCT05490836 - Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients N/A
Recruiting NCT04543565 - Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study Phase 3
Active, not recruiting NCT02894918 - A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs Phase 4
Not yet recruiting NCT02793791 - Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients N/A
Recruiting NCT02287857 - Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B N/A
Recruiting NCT01965418 - A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Phase 4
Recruiting NCT01491295 - Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Phase 4
Terminated NCT01872988 - Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma Phase 3
Recruiting NCT01487876 - Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients Phase 2
Not yet recruiting NCT01436539 - Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Phase 4
Completed NCT01531166 - A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon N/A
Recruiting NCT01360879 - Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease N/A